 |
市場調查報告書
商品編碼
1672882
高血鈣治療市場：依藥物、嚴重程度、通路和地區分類Hypercalcemia Treatment Market, By Drug, By Severity, By Distribution Channel, By Geography |
||||||
2025 年全球高血鈣治療市場規模估計為 46.9 億美元，預計到 2032 年將達到 83.6 億美元，2025 年至 2032 年的複合年成長率為 8.6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 46.9億美元 |
| 效能資料 | 從 2020 年到 2024 年 | 預測期 | 2025 至 2032 年 |
| 預測期：2025-2032年複合年成長率： | 8.60% | 2032 年價值預測 | 83.6億美元 |
高血鈣症是一種以血液中鈣含量異常高為特徵的疾病。當正常的鈣調節系統受到干擾，導致副甲狀腺過量分泌副甲狀腺素(PTH) 或骨吸收過多時，就會發生這種情況。高血鈣症的常見原因包括原發性副甲狀腺機能亢進症、某些癌症、類肉瘤病以及過量維生素 D 或鈣補充劑。如果不及時治療，高血鈣會對多個器官產生嚴重影響，包括腎臟、心臟和消化道。這會導致脫水、噁心、虛弱、精神錯亂，嚴重的話還會導致昏迷。目前的治療包括使用雙磷酸鹽、抑鈣素和抑制鈣重吸收和排泄的糖皮質激素等藥物。然而，安全性和耐受性較佳的新型療法仍具有市場潛力。
市場動態：
全球高血鈣治療市場的成長是由原發性副甲狀腺機能亢進症、某些癌症的盛行率上升以及預期壽命的增加所推動的。此外，多發性骨髓瘤和乳癌患者中經常會出現鈣水平升高的情況。然而，隨著重磅藥物專利的到期，學名藥的出現可能會抑制市場的成長。開發針對鈣敏感受體的新型鈣調劑和治療劑提供了有利可圖的機會。主要企業的區域擴張和與當地製藥公司的合作可能會進一步推動創新治療方案的商業化。
本研究的主要特點
本報告對全球高鈣血症治療市場進行了詳細分析，並提供了預測期（2025-2032）的市場規模和年複合成長率（CAGR%），假設 2024 年為基準年。
它還強調了各個領域的潛在商機並說明了該市場的引人注目的投資提案矩陣。
它還提供了關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
全球高鈣血症治療市場的主要企業是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行介紹的。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球高鈣血症治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球高血鈣治療市場的各種策略矩陣來促進他們的決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管情景
- 產品發布/核准
- PEST分析
- PORTER 分析
- 併購情景
- 流行病學
4. 高血鈣治療市場，依藥物分類，2020-2032 年（十億美元）
- 雙磷酸鹽
- 鈣興奮劑
- 抑鈣素
- 糖皮質激素
- 德努索馬
- 抑鈣素
- 其他
5. 高血鈣治療市場，依嚴重程度，2020-2032 年（十億美元）
- 輕度高血鈣症
- 中度高血鈣症
- 嚴重高血鈣症
6. 高血鈣治療市場，依通路分類，2020-2032 年（十億美元）
- 醫院藥房
- 零售藥局
- 網路藥局
7. 2020 年至 2032 年全球高血鈣治療市場，按地區分類，金額（十億美元）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第8章 競爭格局
- Pfizer, Inc.
- Ascendis Pharma
- Amgen Inc.
- Cipla
- Hikma Pharmaceuticals, PLC
- Apotex Inc.
- Mylan NV
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkem Labs
- Crinetics Pharmaceuticals, Inc.
第9章分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第10章參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Global Hypercalcemia Treatment Market is estimated to be valued at USD 4.69 Bn in 2025 and is expected to reach USD 8.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.69 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.60% | 2032 Value Projection: | USD 8.36 Bn |
Hypercalcemia is a condition characterized by abnormally high levels of calcium in the blood. It occurs when the normal calcium regulatory system is disrupted and the parathyroid glands overproduce parathyroid hormone (PTH) or when bone resorption increases excessively. Some common causes of hypercalcemia include primary hyperparathyroidism, certain types of cancer, sarcoidosis, and excessive vitamin D or calcium supplementation. If left untreated, hypercalcemia can have severe consequences impacting multiple organs like kidneys, heart, and gastrointestinal tract. It may lead to dehydration, nausea, weakness, confusion, and in severe cases, coma. The current treatment landscape involves medications like bisphosphonates, calcitonin, and glucocorticoids that help reduce calcium resorption and excretion. However, the market still remains open for novel therapies with improved safety and tolerability profiles.
Market Dynamics:
The global hypercalcemia treatment market growth is driven by the rising prevalence of primary hyperparathyroidism, certain types of cancers, and increasing life expectancy. In addition, high calcium levels are frequently observed in patients with multiple myeloma and breast cancer. However, the market growth can be restrained by the availability of generic versions once patents expire on blockbuster drugs. The development of novel calcimimetics and therapies targeting calcium-sensing receptors provide lucrative opportunities. Regional expansions by key players and partnerships with local pharma companies will further aid commercialization of innovative treatment options.
Key Features of the Study:
This report provides in-depth analysis of the global hypercalcemia treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hypercalcemia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Inc., Ascendis Pharma, Amgen Inc., Cipla, Hikma Pharmaceuticals, PLC, Apotex Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Sumitomo Pharma Co., Ltd., Alkem Labs, and Crinetics Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypercalcemia treatment market
Market Segmentation
- By Drug Insights (Revenue, USD Bn, 2019 - 2032)
- Bisphosphonates
- Calcimimetic Agents
- Calcitonin
- Glucocorticoids
- Denusomab
- Calcitonin
- Others
- By Severity Insights (Revenue, USD Bn, 2019 - 2032)
- Mild Hypercalcemia
- Moderate Hypercalcemia
- Severe Hypercalcemia
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2019 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer, Inc.
- Ascendis Pharma
- Amgen Inc.
- Cipla
- Hikma Pharmaceuticals, PLC
- Apotex Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkem Labs
- Crinetics Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hypercalcemia Treatment Market, By Drug
- Hypercalcemia Treatment Market, By Severity
- Hypercalcemia Treatment Market, By Distribution Channel
- Hypercalcemia Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
4. Hypercalcemia Treatment Market, By Drug, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcimimetic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcitonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Glucocorticoids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Denusomab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcitonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Hypercalcemia Treatment Market, By Severity, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Mild Hypercalcemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Moderate Hypercalcemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Severe Hypercalcemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Hypercalcemia Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Hypercalcemia Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Severity, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ascendis Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals, PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alkem Labs
- Crinetics Pharmaceuticals, Inc.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
